Hybridoma Development & Screening

It has been said that “you get what you screen for”. Hence, we believe that the hybridoma screening cascade must be carefully designed and executed in order to identify the rare antibody events that are inherent to antibody discovery programs.

Screening is one of the most important parts of the hybridoma development work flow. Aragen antibody discovery scientists work collaboratively with the client to design the most appropriate antibody screening strategy to identify target specific and high affinity antibodies. Our extensive screening procedures cover:

  • Sero-conversion
  • Antigen reactivity
  • Epitope binning
  • Affinity determination using the ForteBio OctetRED system
  • Cell based binding and activity
  • Cross reactivity

In addition to our standard fusions using whole cells from spleen and lymph nodes, we also offer fusions using isolated B-cells to enrich the antibody secreting B-cell population. Although hybridoma culture supernatants are primarily screened in-house using our high-throughput ELISA and FACS-based assays, we also encourage clients to perform additional screening at their facility to confirm specificity and also to confirm the presence of the protein. Proper controls are included in the screening assays to verify specificity and cross-reactivity.